• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
healthcare providers

Shalini Shenoy, MD

Healthcare Provider
Professor of Pediatrics
Washington University School of Medicine
Medical Building Three
1020 N. Mason Road
Suite 110
St. Louis, Missouri, United States

Dr. Shenoy is currently working as professor of pediatrics in the division of Hematology/Oncology and General Pediatrics at Washington University School of Medicine. She also serves as Director, Pediatric Stem Cell Transplant Program at St. Louis Children’s Hospital.

She is the prinicipal investigator of national trials of unrelated donor transplantation for severe sickle cell disease termed as the SCURT Trial (Bone Marrow Transplant Clinical Trials Network 0601, NHLBI) and thalassemia termed as the URTH Trial (Thalassemia Clinical Research Network, NHLBI).

Dr. Shenoy’s research interests are focused on stem cell transplants for non-malignant disorders, reduced intensity transplants, and the immunologic mechanisms of graft rejection, graft versus host disease (GVHD), and immune reconstitution following stem cell transplantation (SCT).


Representative Publications:

Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial

Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation

Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia

A trial of unrelated donor marrow transplantation for children with severe sickle cell disease

Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions

Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends

Has stem cell transplantation come of age in the treatment of sickle cell disease?

Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease

expertly curated content related to this topic

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.